ATC Group: L01EX28 Repotrectinib

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01EX28 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01E Protein kinase inhibitors
4 L01EX Other protein kinase inhibitors
5 L01EX28

Active ingredients in L01EX28

Active Ingredient

Repotrectinib is an inhibitor of proto-oncogene tyrosine-protein kinase ROS1, the tropomyosin receptor tyrosine kinases (TRK) TRKA, TRKB, TRKC, and anaplastic lymphoma kinase (ALK). Repotrectinib has demonstrated in vitro and in vivo inhibition of cell lines expressing the targeted fusion oncogenes ROS1, TRKA, TRKB, TRKC, and corresponding mutations (ROS1G2032R, ROS1D2033N, TRKAG595R, TRKBG639R, TRKCG623R).

Related product monographs

Document Type Information Source  
 AUGTYRO Capsule MPI, US: SPL/PLR FDA, National Drug Code (US)
 AUGTYRO Capsule, hard MPI, EU: SmPC European Medicines Agency (EU)

United States medicines

Medicines classified under this ATC code globally

Lithuania (LT)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

Go to ATC index
⇈